How to do Primary Angioplasty. - Patients with Cardiogenic Shock
|
|
|
- Suzan Benson
- 5 years ago
- Views:
Transcription
1 How to do Primary Angioplasty - Patients with Cardiogenic Shock Advanced Cardiovascular Intervention 2011 Dan Blackman Leeds General Infirmary
2 MY CONFLICTS OF INTEREST ARE: Research Grants Medicines Company Advisory Board Medicines Company Lilly
3 Causes of Cardiogenic Shock Tamponade/rupture 1.7% Isolated RV Shock 3.4% Other 7.5% VSD 4.6% Acute Severe MR 8.3% Shock Registry JACC :1063 Predominant LV Failure 74.5%
4 In-hospital Mortality (%) Survival from mechanical causes 100% 90% 94% No Surgery Surgery Percutaneous closure 80% 70% 71% 60% 50% 47% 40% 39% 30% 28% 20% 10% 0% VSD Shock Registry JACC 2000;36:1104 & 36: 1110 Acute Severe MR GUSTO 1 Circulation 2000;101:27 Holzer R CCI 2004;61:196
5 Mortality (%) Emergency revascularisation - SHOCK Trial 90% 80% 70% p=0.11 p= % p= % p= % 80% ERV IMS 60% 50% 47% 56% 50% 53% 40% 30% 20% 10% 0% 30 days (n=302) 6 months (n=301) 12 months (n=299) 6 years 85% of survivors NYHA Class I/II at 12 months Hochman JAMA 2000;285:190
6 1-year mortality (%) Single or Multi-vessel PCI? 81% of PCI patients multi-vessel disease 85% PCI IRA only; 23% complete revascularisation 90% 80% 80% 70% 60% 50% p< % p=ns 50% p=ns 54% 46% 40% 39% 30% 20% 10% 0% MV PCI SV PCI Complete Partial Shock Trial MV PCI SV PCI Shock Registry
7 1-year mortality (%) Role of CABG 60% 53% p=ns 50% 48% 46% 40% 30% 20% 24% PCI CABG 10% 0% SHOCK Trial SHOCK Registry n=81 n=47 n=276 n=109 SHOCK Trial CABG vs PCI baseline characteristics LMS Disease 41% vs 13% p= VD 80% vs 60% p=0.18 Diabetes 49% vs 27% p=0.11
8 AHA/ACC Guidelines for Revascularisation
9 PCI Strategy in Cardiogenic Shock Stabilise the patient first, open the vessel second Up-front IABP Central venous access Inotropic/Pressor support as required Anaesthetic support in the cath lab
10 SOAP II Comparison of Dopamine and Norepinephrine in Shock 1679 patient RCT in shock 280 patients cardiogenic Increased arrythmia with dopamine (AF/VT/VF) Significantly lower mortality with norepinephrine in CS Vasoconstriction (by SVR) is often absent* Patients with vasoconstriction have better outcome* De Backer, NEJM, 2010;362:779.
11 Cardiogenic Shock Systolic BP >100mmHg Systolic BP mmHg NO Shock Systolic BP mmHg With Shock Systolic BP <70mmHg With Shock Nitroglycerin 10-20mcg/min Dobutamine 2-20mcg/kg/min Dopamine 5-15mcg/kg/min Norepinephrine 1-30mcg/kg/min Antmen, JACC, 2004;44:671
12 30 day Mortality (%) Abciximab in Cardiogenic Shock 70% 60% 62% PCI PCI +Abciximab 50% 44% 44% 40% 36% 39% 30% 20% 22% 26% 22% 21% 10% 9% 0% Antoniucci (stent) n=77 Chan Stent Chan PTCA Giri (50% stent) n=41 n=55 n=113 ADMIRAL (stent) n=25
13 Event rate (%) 80 patient RCT PRAGUE-7 study Up-front (n=40) vs provisional (n=40) abciximab in PPCI for cardiogenic shock 120% 100% 100% Up-front Provisonal 80% P=NS for all 60% 40% 35% 37% 32% 42% 27% 20% 10% 5% 0% Abciximab given Mortality MACE TIMI Major Bleeding
14 Mortality (%) Intra-aortic balloon pump counterpulsation TT only TT + IABP Shock Registry (n=292) NRMI Registry (n=23,180) TACTICS GUSTO I & III Kovack (n=46)
15 In-hospital Mortality (%) IABP in Cardiogenic Shock Primary PCI Retrospective analysis of 23,180 patients from NRMI database 7268 treated by IABP Thrombolysis only Thrombolysis + IABP Primary PCI only Primary PCI + IABP
16
17 Event rate (%) Timing of IABP in Cardiogenic Shock Primary PCI 40% 35% 35% IABP pre (n=62) IABP post/none (n=57) 35% 30% 30% 25% 20% 15% 15% 13% 15% 10% 5% 0% CPR VF/VT arrest Any event Single centre registry Primary PCI for shock Brodie AJC 1999;84:18
18 Left atrial-to-femoral arterial LVAD Low speed centrifugal continuous flow pump 21F venous transeptal cannula 17F arterial cannula Maximum flow 4L/minute Expensive +++ Tandem Heart plvad
19 30 day mortality (%) Tandem Heart Outcome Data 50% 45% 42% 45% p=ns 47% Tandem Heart IABP 40% 35% 36% 30% 25% 20% 15% 10% 5% 0% Thiele (n=41) Burkhoff (n=33) Improved haemodynamic parameters Increase in bleeding, limb ischaemia, and sepsis Thiele EHJ 2005;26:1276. Burkhoff AHJ 2006;152:e1
20 Impella Axial flow pump Much simpler to use Increases cardiac output & unloads LV LP F percutaneous approach; Maximum 2.5 L flow LP F surgical cutdown; Maximum 5L flow Expensive ++ Blood Inlet Motor Blood outlet Pressure Lumen
21 Impella outcome data ISAR-SHOCK 26 patient RCT Impella vs IABP Cardiac Index, MAP (by 10mmHg) vs IABP Complications IABP No difference in mortality PROTECT-II 654 patients RCT IABP vs Impella in high-risk PCI Stopped after n= 305 due to futility Primary EP composite of 10 MAEs Incidence 38% Impella vs 43% IABP
22 How to treat STEMI + Cardiogenic Shock Emergency angiography and revascularisation On-table echo to rule out mechanical defects Stabilise the patient in the lab before revascularisation IABP Central venous access Pressors if required Norepinephrine (dopamine) Anaesthetic support Consider calling the surgeon for true surgical disease PCI culprit artery. Consider other vessels if shock persists. Staged PCI or CABG if patient stabilises Consider percutaneous VAD if shock persists with IABP + effective revascularisation
23 ESC Guidelines for Cardiogenic Shock
24 Revascularisation: SHOCK trial STEMI complicated by shock due to LV failure n= 302 Hypotension (SBP<90mmHg), End organ hypoperfusion, CI<2.2, PCWP>15mmHg Randomised within 36 hours of index event Emergency Revascularisation (152) PCI or CABG within 6hr IABP recommended Medical (150) IABP Revasc at 54 hours PCI = 81 and CABG = 47 Primary endpoint: 30 day mortality Secondary endpoint: 6 and 12 month mortality Late follow-up
25 NYHA I-II NYHA III-IV Death Sleeper, JACC, 2005; 46:266. Heart Attack: The Challlenge, Manchester 2010 Shock: Incidence, Diagnosis, Treatment, Outcome
26 30-day Mortality (%) Emergency revascularisation in the Elderly - SHOCK Trial 80% 70% 75% p=0.01 ERV IMS 60% p= % 53% 50% 40% 41% 30% 20% 10% 0% <75 years (n=246) >75 years (n=56) >75 years ERV vs IMS baseline characteristics LVEF 28% vs 36% p=0.051 Anterior MI 63% vs 41% p=0.18 Female 54% vs 31% p=0.11
27 30-day Mortality (%) Elderly - SHOCK & other registry data 90% 80% 70% 81% ERV IMS 60% 50% 48% 47% 46% 40% 30% 20% 10% 0% SHOCK Registry Mayo Clinic Northern New n=44 n=233 n=61 England n=74
28 Why worry about Cardiogenic Shock? Cardiogenic shock complicates 6-8% of STEMI * Mortality is 60.1% ** It is the leading cause of death from STEMI * GUSTO, NRMI, GRACE ** Shock registry JACC 2000
29 ESC Guidelines for Revascularisation Complete revascularisation has been recommended with PCI in all critically stenosed large epicardial coronary arteries
30 Right Ventricular Infarction (3%) Shock with clear lungs Elevated JVP ECG and echo Maintain preload Reduce RV afterload Maintain AV synchrony
31 Mortality by PCI outcomes TIMI FLOW 85 SuccUnsucc PCI Webb, JACC 2003;42:1380.
32 Percutaneous left ventricular assist devices Even with revascularisation and IABP support mortality from cardiogenic shock post STEMI remains 50% Recovery of myocardial performance following successful revascularisation may take several days. During this time many patients succumb to low cardiac output Efficacy of IABP is limited by the lack of active cardiac support, requirement for a certain level of LV function, and the need for accurate synchronisation with cardiac cycle Patients with severely impaired LV function and/or persistent tachyarrhythmias derive little benefit from IABP
33 Management Principles Diagnose & treat causes other than LV failure Support cardiac output and organ perfusion Inotropes / pressors Mechanical support Early Revascularisation PCI/CABG
34 Agent Inotropes and Vasopressors Dose μg/min α vasoconstrict β Inotropy/vasodilate Arrhythmia Epinephrine Norepinephrine Dopamine Dobutamine Isoproterenol Vasoconstriction (by SVR) is often absent* Patients with vasoconstriction have better outcome* * SHOCK Data
35 PCI + staged CABG Chiu et al Single centre retrospective registry study PCI only vs PCI + staged CABG for cardiogenic shock with multivessel disease Propensity matched n=44 in each group 1.3 vessels revascularised by PCI; 2.6 by CABG 30-day mortality 20.5% PCI + CABG vs 40.9% PCI only
ST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary Conflicts of interest Advisory Boards Cordis Boston Scientific
Assist Devices in STEMI- Intra-aortic Balloon Pump
Assist Devices in STEMI- Intra-aortic Balloon Pump Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center Athens, Greece Cardiogenic shock 5-10% of pts after a heart attack 60000-70000 pts in Europe/year
Cardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland
Management of Cardiogenic shock. Prof. Christian JM Vrints
Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease
STEMI and Cardiogenic Shock. The rules and solution. Dave Kettles St Dominics and Frere Hospitals East London ZA
STEMI and Cardiogenic Shock. The rules and solution Dave Kettles St Dominics and Frere Hospitals East London ZA Definitions: Shock is a life threatening, but initially reversible state of cellular and
Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)
Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO) Michael A. Gibson, MD Assistant Professor of Medicine University of California, Irvine Division of Cardiology
A Future for the IABP in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany
A Future for the in Cardiogenic Shock? Holger Thiele Medical Clinic II (Cardiology/Angiology/Intensive Care) University of Lübeck, Germany Disclosures Funding: German Research Foundation German Heart Research
Percutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI
Percutaneous Mechanical Circulatory Support for Cardiogenic Shock 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI The Need for Circulatory Support Basic Pathophysiologic Problems:
Rationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
Οξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση. Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας
Οξύ στεφανιαίο σύνδρομο και καρδιογενής καταπληξία. Επεμβατική προσέγγιση Σωτήριος Πατσιλινάκος Κωνσταντοπούλειο Γ.Ν. Ν. Ιωνίας ACUTE HEART FAILURE AND CAD: ACS / LV ischaemic dysfunction Mechanical complications
MANAGEMENT OF CARDIOGENIC SHOCK
MANAGEMENT OF CARDIOGENIC SHOCK CASE PRESENTATION 37 year old Dutch female No known coronary artery disease risk factors 1 week post partum at time of presentation (G3P3) after an uncomplicated normal
PHARMACOLOGICAL MANAGEMENT OF CARDIOGENIC SHOCK
PHARMACOLOGICAL MANAGEMENT OF CARDIOGENIC SHOCK Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva,
The Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize
The Role of Mechanical Circulatory Support in Cardiogenic Shock: Presented by Nancy Scroggins ACNP, CNS-CC CV Surgery ACNP Bayshore Medical Center The Role of Mechanical Circulatory Support in Cardiogenic
Management of Acute Shock and Right Ventricular Failure
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering, Cleveland Clinic NONE Disclosures CARDIOGENIC SHOCK
Acute Myocardial Infarction Complicated by Cardiogenic Shock
Acute Myocardial Infarction Complicated by Cardiogenic Shock Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional
Cardiogenic Shock in Acute MI
Cardiogenic Shock in Acute MI Mark Sheldon, MD UNMH Interventional Cardiology Objectives Overview Treatment Definition Shock profiles Causes Medical Mechanical Illustrative case Questions? Revascularization
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Multivessel disease and cardiogenic shock: CABG is the optimal revascularization therapy. Contra Prof. Christian JM Vrints Cardiogenic Shock Spiral Acute Myocardial
Who is the high risk patient?
Who is the high risk patient? High risk of periprocedural death or other major complications (hemodynamic compromise, MI, stroke, dialysis) Contributors of Risk Lesion/Procedure Governed by 1. Patient
Bridging With Percutaneous Devices: Tandem Heart and Impella
Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE
Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands
Cardiogenic Shock Dr. JPS Henriques Academic Medical Center University of Amsterdam The Netherlands Conflict of interest disclosure Research grant Abbott Vascular Research grant Abiomed Inc. Global Impella
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017
Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017 Pascal Vranckx MD, PhD. Medical director Cardiac Critical Care Services Hartcentrum Hasselt Belgium Disclosure
PUMP FAILURE COMPLICATING AMI: ISCHAEMIC VSR
PUMP FAILURE COMPLICATING AMI: ISCHAEMIC VSR Dr Susanna Price MD PhD MRCP ESICM FFICM FESC Consultant Cardiologist & Intensivist Royal Brompton & Harefield NHS Foundation Trust DECLARATIONS Educational
Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist
Dr Stephen Pettit, Consultant Cardiologist Cardiogenic shock Management of Cardiogenic Shock Outline Definition, INTERMACS classification Medical management of cardiogenic shock PA catheters and haemodynamic
Cardiogenic shock: Current management
Cardiogenic shock: Current management Janine Pöss Universitätsklinikum des Saarlandes Klinik für Innere Medizin III Kardiologie, Angiologie und internistische Intensivmedizin Homburg/Saar I have nothing
Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ
Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ Low cardiac output/cardiogenic Shock State of end-organ hypoperfusion due to cardiac failure.
Why we need a consensus document on cardiogenic shock? ACCA Masterclass 2017
Why we need a consensus document on cardiogenic shock? ACCA Masterclass 2017 Holger Thiele Cardiogenic Shock STEMI Guidelines Steg et al. Eur Heart J.2012;33:2569-2619 Cardiogenic Shock CHF Guidelines
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
Cardiogenic Shock Nick Tehrani, MD Definition TREATMENT OPTIONS IN CARDIOGENIC SHOCK WITH INTRA-AORTIC BALLOON COUNTERPULSATION
TREATMENT OPTIONS IN CARDIOGENIC SHOCK WITH INTRA-AORTIC BALLOON COUNTERPULSATION *Markus W. Ferrari Clinic of Internal Medicine I, HELIOS Dr-Horst-Schmidt-Clinic, Wiesbaden, Germany *Correspondence to
Introduction to Acute Mechanical Circulatory Support
Introduction to Acute Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive
Percutaneous Mechanical Circulatory Support Devices
Percutaneous Mechanical Circulatory Support Devices Daniel Vazquez RN, RCIS Miami Cardiac & Vascular Institute FINANCIAL DISCLOSURES none CASE STUDY CASE STUDY 52 year old gentlemen Complaining of dyspnea
Circulatory Support: From IABP to LVAD
Circulatory Support: From IABP to LVAD Howard A Cohen, MD, FACC, FSCAI Director Division of Cardiovascular Intervention Co Director Cardiovascular Interventional ti Laboratories Lenox Hill Heart & Vascular
STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia.
STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia. PART 1 Systems of care for STEMI. STEMI Management Coronary angiogram +/- stenting. Prehospital thrombolysis
New Horizons in Cardiogenic Shock. Timothy D. Henry, MD Director of Cardiology Cedars-Sinai Heart Institute
New Horizons in Cardiogenic Shock Timothy D. Henry, MD Director of Cardiology Cedars-Sinai Heart Institute AMI Shock Mortality Unchanged in > 20 years 74355 US AMI/CGS cases per year 1,2 78954 78500 79823
Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD
A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD NAVAL HOSPITAL OF ATHENS case presentation Female, 81yo Hx: diabetes mellitus, hypertension, chronic anaemia presented
IABP SHOCK II trial:
IABP SHOCK II trial: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic
CARDIOGENIC SHOCK. Antonio Pesenti. Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI)
CARDIOGENIC SHOCK Antonio Pesenti Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI) Primary myocardial dysfunction resulting in the inability of the heart to mantain an
Counterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece
John N. Nanas, MD, PhD Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece History of counterpulsation 1952 Augmentation of CBF Adrian and Arthur Kantrowitz, Surgery 1952;14:678-87
Approach to Multi Vessel disease with STEMI
Approach to Multi Vessel disease with STEMI MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION Dr. Thomas Alexander, M.D; D.M; F.A.C.C. Senior Consultant and Interventional Cardiologist Kovai Medical Centre
Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California
High Risk PCI Making Possible the Impossible Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California Disclosures Abiomed Research Support Consulting Agreement
Guideline compliance, utilization trends
Guideline compliance, utilization trends and device selection Tilmann Schwab Cardiology / Intensive care Cardiac support IABP LVAD Transluminal l LVAD Cardiac support Emergency cardiac life support (ECLS)
Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
Mechanics of Cath Lab Support Devices
Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Chief Medical Officer First Coast Cardiovascular Institute, Jacksonville, FL Professor of Medicine, UCF, Orlando, FL None DISCLOSURE Percutaneous
Rationale for Left Ventricular Support During Percutaneous Coronary Intervention
Rationale for Left Ventricular Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Associate Professor, Division of Cardiology Director, Acute Circulatory Support Program
MODULE 2 THE CLINICAL ENIGMA: RANDOMIZED TRIALS vs CLINICAL PRACTICE. Nico H. J. Pijls, MD, PhD Catharina Hospital Eindhoven The Netherlands
MODULE 2 THE CLINICAL ENIGMA: RANDOMIZED TRIALS vs CLINICAL PRACTICE Nico H. J. Pijls, MD, PhD Catharina Hospital Eindhoven The Netherlands Disclosure All presenters have a speaker agreement with Maquet
Definition. Low-cardiac-output state resulting in life threatening end-organ hypoperfusion. Criteria: MAP 30 mm Hg lower than baseline)
Definition Low-cardiac-output state resulting in life threatening end-organ hypoperfusion Criteria: 1. Persistent hypotension (SBP
TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA. IMP v4
1 TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA FDA APPROVES IMPELLA FOR HIGH-RISK PCI 2 Impella is the only hemodynamic support device proven safe and effective in elective
STEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
HOW TO PERFORM LEFT VENTRICULAR ASSISTANCE IN THE CATHLAB. Andreas Baumbach, MD FESC FRCP Bristol Heart Institute University Hospitals Bristol UK
HOW TO PERFORM LEFT VENTRICULAR ASSISTANCE IN THE CATHLAB Andreas Baumbach, MD FESC FRCP Bristol Heart Institute University Hospitals Bristol UK Disclosure I have no conflicts of interest regarding this
Rhondalyn C. McLean. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VII, A. Study Purpose and Rationale
A Randomized Clinical Study To Compare The Intra-Aortic Balloon Pump To A Percutaneous Left Atrial-To-Femoral Arterial Bypass Device For Treatment Of Cardiogenic Shock Following Acute Myocardial Infarction.
LV Assist in High Risk PCI and Cardiogenic Shock: Is it Worth the Effort?
LV Assist in High Risk PCI and Cardiogenic Shock: Is it Worth the Effort? Vincent J. Pompili, MD, FACC, FSCAI Professor of Internal Medicine Director of Interventional Cardiovascular Medicine and Cardiac
M/39 CC D. => peak CKMB (12 hr later) ng/ml T.chol/TG/HDL/LDL 180/150/48/102 mg/dl #
Acute Coronary Syndrome - Case Review - Young-Guk Ko, MD Yonsei Cardiovascular Center Yonsei University College of Medicine Case 1 M/39 #4306212 CC D : Severe squeezing chest pain : 4 hours, aggravated
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 OSPEDALE Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
Disclosures. Objectives 10/11/17. Short Term Mechanical Circulatory Support for Advanced Cardiogenic Shock. I have no disclosures to report
Short Term Mechanical Circulatory Support for Advanced Cardiogenic Shock Christopher K. Gordon MSN, ACNP-BC Disclosures I have no disclosures to report 1. Pathophysiology 2. Epidemiology 3. Assessment
AllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012 Lucia Jewbali cardiologist-intensivist 14 beds/8 ICU beds Acute coronary syndromes Heart failure/ Cardiogenic shock Post cardiotomy Heart
Mechanics of Cath Lab Support Devices
Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida DISCLOSURE Presenter:
4/22/2016 Updated. AllinaHealthSystem. Cardiogenic Shock: Definition. No Disclosures. Cardiogenic Shock: Declining (But Still High) Case Fatality Rate
4/22/216 Updated Definition End-organ hypoperfusion secondary to cardiac failure Advanced Cardiopulmonary Support for the Critically Ill Adult April 22, 216 Cardiogenic Shock Michael A. Samara, MD FACC
The development of cardiogenic shock portends an extremely poor prognosis. Cardiogenic Shock: A Lethal Complication of Acute Myocardial Infarction
TREATMENT UPDATE Cardiogenic Shock: A Lethal Complication of Acute Myocardial Infarction David R. Holmes, Jr, MD Mayo Graduate School of Medicine, Mayo Clinic, Rochester, MN Cardiogenic shock is a serious
Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
Recovering Hearts. Saving Lives.
Recovering Hearts. Saving Lives ṬM The Door to Unload (DTU) STEMI Safety & Feasibility Pilot Trial November 218 Recovering Hearts. Saving Lives. LEGAL DISCLAIMERS This presentation includes select slides
Impella Ins & Outs. CarVasz November :45 12:15
Impella Ins & Outs CarVasz November 21 2014 10:45 12:15 Nicolas M. Van Mieghem, MD, PhD, FESC Clinical Director of Interventional Cardiology Thoraxcenter, Erasmus MC Rotterdam Background IABP is widely
Case - Advanced HF and Shock (INTERMACS 1)
Case - Advanced HF and Shock (INTERMACS 1) Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive Director,
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
Cardiogenic Shock and Initiatives to Reduce Mortality
Cardiogenic Shock and Initiatives to Reduce Mortality Tanveer Rab, MD, FACC William O Neill, MD, FACC Perwaiz Meraj, MD, FACC Alex Truesdell, MD, FACC The Golden Hours? 50% dead within 10 hours Overall
CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock. Holger Thiele, MD on behalf of the CULPRIT-SHOCK Investigators
CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock Holger Thiele, MD on behalf of the CULPRIT-SHOCK Investigators Disclosure Statement of Financial Interest Within the past 12 months,
เอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
King s Research Portal
King s Research Portal DOI: 10.15420/icr.2016.11.1.39 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Joseph, J., Patterson,
Case year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50
Case 1 65 year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50 Case 1 65 year old female nursing home resident with
Cindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
Management of ST-elevation myocardial infarction Update 2009 Late comers: which options?
European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth
What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN
What is new in the Treatment of STEMI? Malcolm R. Bell, MBBS Mayo Clinic Rochester, MN October 2011 Part 2 Summary of newer antithrombotic and antiplatelet agents in STEMI Role of thrombectomy in PPCI
Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.
UvA-DARE (Digital Academic Repository) Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E. Link to publication Citation for published version
Ted Feldman, M.D., MSCAI FACC FESC
Support Technologies and High Risk Intervention Patient Selection: When Not to Use Them Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas December 7-10 th, 2014 Ted
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
Antonio Colombo. Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy. Miracor Symposium. Speaker: 15. Parigi: May 16-19, 2017
Parigi: May 16-19, 2017 Miracor Symposium Speaker: 15 Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy Nothing to disclose PiCSO Impulse System Elective high risk
Controversies in Cardiogenic Shock. Timothy D. Henry, MD Cedars-Sinai Heart Institute
Controversies in Cardiogenic Shock Timothy D. Henry, MD Cedars-Sinai Heart Institute Key Issues Cardiac Arrest-Cardiogenic shock interaction New SCAI Classification Refractory Shock Shock with Multivessel
BY AMAR R. CHADAGA, MD, AND TIMOTHY A. SANBORN, MD
Percutaneous Coronary Intervention in Cardiogenic Shock A review of the current and evolving percutaneous interventions. BY AMAR R. CHADAGA, MD, AND TIMOTHY A. SANBORN, MD Cardiogenic shock represents
Mechanical circulatory support in cardiogenic shock
European Heart Journal (2014) 35, 156 167 doi:10.1093/eurheartj/eht248 REVIEW Novel devices Mechanical circulatory support in cardiogenic shock Karl Werdan 1 *, Stephan Gielen 1, Henning Ebelt 1, and Judith
Cardiogenic Shock Protocol
Cardiogenic Shock Protocol Impella Devices Best Practices in AMI Cardiogenic Shock Identify 1-3 SBP < 90 mmhg or on inotropes /pressors Cold, clammy, tachycardia Lactate elevated > 2 mmoi /L Stabilize
Relax and Learn At the Farm 2012
Relax and Learn At the Farm Session 9: Invasive Hemodynamic Assessment and What to Do with the Data Carol Jacobson RN, MN Cardiovascular Nursing Education Associates Function of CV system is to deliver
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
Acute Mechanical Circulatory Support Right Ventricular Support Devices
Acute Mechanical Circulatory Support Right Ventricular Support Devices Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure
Patient Transfer. Mark de Belder The James Cook University Hospital Middlesbrough
Patient Transfer Mark de Belder The James Cook University Hospital Middlesbrough Current Management Strategies for ACS ACS No ST Elevation ST ST Elevation Elevation Early Invasive Early Conservative Fibrinolysis
Alex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
Emergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
University of Leipzig Heart Center
Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock Holger
Li Xu 1, MD, Hao Sun 1, MD, Le-Feng Wang 1, MD, Xin-Chun Yang 1, MD, Kui-Bao Li 1, MD, Da-Peng Zhang 1, MD, Hong-Shi Wang 1, MD, Wei-Ming Li 1, MD
Singapore Med J 2016; 57(7): 396-400 doi: 10.11622/smedj.2016121 Long-term prognosis of patients with acute myocardial infarction due to unprotected left main coronary artery disease: a single-centre experience
Extra Corporeal Life Support for Acute Heart failure
Extra Corporeal Life Support for Acute Heart failure Benjamin Medalion, MD Director Heart and Lung Transplantation Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Campus, Israel Mechanical
Images have been removed from the PowerPoint slides in this handout due to copyright restrictions.
Percutaneous Coronary Intervention https://www.youtube.com/watch?v=bssqnhylvma Types of PCI Procedures Balloon Angioplasty Rotational Atherectomy Coronary Stent Balloon Inflation Rotational Atherectomy
Cardiogenic shock (CS) remains
The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction patients presenting with severe and profound cardiogenic shock: The Academic Medical Center intensive care unit experience* Annemarie
The right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
When Aspiration Thrombectomy Does Not Work? A A R O N W O N G N A T I O N A L H E A R T C E N T R E S I N G A P O R E
When Aspiration Thrombectomy Does Not Work? A A R O N W O N G N A T I O N A L H E A R T C E N T R E S I N G A P O R E Thrombus in STEMI Over 70% of STEMI patients has angiographic evidence of thrombus
Fractional Flow Reserve: Review of the latest data
Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most
Dave Kettles, St Dominics Hospital East London.
Dave Kettles, St Dominics Hospital East London. 110 x 150 Angina for a couple of months Trop T negative T wave inversion across the chest leads Not wanting to risk radial Huge struggle with femoral